The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
Disclosed is the use of a combination of an aromatase inhibitor such as atamestane, formestane, fadrozole, letrozole, pentrozole, anastrozole and vorozole, a progestin such as norgestrel, levonorgestrel, norethindrone, norethindrone acetate…
The invention relates to the use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the manufacture of a medicament for the treatment of endometriosis. The invention also relates to pharmaceutical formulations comp…
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.
The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.